Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuclea Biotechnologies Partners with IBL-America

Published: Tuesday, February 25, 2014
Last Updated: Monday, February 24, 2014
Bookmark and Share
Nuclea to become primary serum HER-2/neu kit distributor in US.

Nuclea Biotechnologies, Inc. has recently announced that Immuno-Biological Laboratories Inc., (IBL-America) would be their primary US distributor for the serum HER-2/neu kits.

IBL-America, based in Minneapolis, MN, is a distributor of high quality diagnostic assays in various areas including autoimmunity, endocrinology, infectious disease, oncology, and neuroscience and offers technical laboratory services as well.

Nuclea is a specialist in serum based oncoprotein diagnostics and offers tests for In Vitro Diagnostic (IVD) and Research Use Only (RUO). Nuclea provides the only FDA-cleared through 510(k) IVD ELISA test for the measurement of serum HER-2/neu in the management and monitoring of women with metastatic breast cancer.

This microtiter based test enables laboratories to measure the level of HER-2/neu in serum in a cost-efficient and validated manner. This test is reimbursed by insurance companies and has a unique CPT code 83950.

Additionally, the two companies will coordinate joint marketing efforts for the serum HER-2/neu kits.

“As we continue to see the market respond to our serum HER-2/neu test, we’ve been securing partners who have strong distribution channels,” said Patrick Muraca, President and CEO of Nuclea. “IBL-America has a proven track record and I’m excited to have them as a partner.”

Mark Kowal, President and CEO of IBL-America stated “We, at IBL-America, are excited about the opportunity to work with the professionals at Nuclea. The HER-2/neu test is an excellent addition to our line of oncology products and we welcome this promising joint venture.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!